
Opinion|Videos|July 22, 2024
Biologic Therapies for Hidradenitis Suppurativa
Author(s)Vivian Shi, MD, FAAD
A dermatologist outlines the role for biologic therapies in the hidradenitis suppurativa treatment landscape and discusses the importance of early intervention.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- What is the “window of opportunity” with anti-inflammatory treatments in HS and why is early intervention with biologic therapies so imperative?
- Which biologic therapies are currently used in HS and what are the important patient considerations you consider before utilizing these?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer
2
Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal
3
First-Line Zongertinib Yields Strong Responses in Patients With Advanced HER2-Mutant NSCLC
4
New Biomarkers, Drug Targets Identified for Colorectal Cancer
5